U.S. Markets closed

DexCom, Inc. (DXCM)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
70.23+0.77 (+1.11%)
At close: 4:00PM EDT

69.63 -0.60 (-0.86%)
After hours: 4:11PM EDT

People also watch
PODDNUVAABMDELGXEW
  • e
    ellquestion authority
    ellquestion authority
    always invest in companies who have helped keep you alive for over 10 years with their tech. stable, well run company, good investment, good products, fair pricing for consumers. a niche market but they have always stayed true to their mission.
  • l
    lotsa luck
    lotsa luck
    Excellent presentation yesterday at MS investor conference. Worth listening to and noting optimistic growth in top line expected in 2nd half and steady growth coming in the coming year. G6 and Verlily codeveloped CGM for type 2 DM market coming next year. Stock likely to start recovery in share price over the rest of the year going into 2018 as medicare patient revenue starts to be acretive to top line growth.
  • A
    Ashley
    Ashley
    DXCM, looks to be overvalued at this price have you guys heard of Awe.Some.Sto-ck.s. i started receiving their allerts and so far i am happy.
  • T
    Tpljmpr5
    Tpljmpr5
    @Dani: Since you are the long term 9 year investor on this name and must know it intimately please tell us why the stock tanked on this great announcement with Fitbit? Waiting.......
  • j
    jybyf
    jybyf

    Ready to start actually beating the markets. You need to check out the dork! https://hotstockstoday1.blogspot.in/

    Stock Market
    hotstockstoday1.blogspot.in
  • G
    Grace
    Grace

    Do you think this thing is done selling? Showing us a buy signal now on DXCM? https://activepennystocks1.blogspot.com just allerted a new stock - it beats having to dig online yourself for new stock ideas.

    Penny Stock
    activepennystocks1.blogspot.com
  • p
    paul
    paul
    TNDM's insulin pump going buyout by Apple
  • p
    paul
    paul
    TNDM's insulin pump pairs w/ Dexcom CGM5 even potentials for both Corp. TNDM IS 80 cents
  • l
    lotsa luck
    lotsa luck
    Today's announcement that MDT has had problems with the manufacturing of it's CGM sensor, raises the likelihood that DXCM will gain an even greater share of the growing CGM market.
  • M
    Montique
    Montique
    Yeah, how u like me now? The rippa will not allow !!!!!! Dolla bill ya'll !!!!! Money 2 be cashed !!!!
  • S
    SMD
    SMD
    Apple will release it's all in one self contained watches soon. I will cause a surge in Dexcom sales due to the perfect compatibility with the Dexcom BG sensors.
  • A
    Anna
    Anna
    Overall I think we will see upside for DXCM in the short-term. Perhaps a pullback next day or so could occur I suppose but are yall also seeing a further leg higher? check out awe-some*sto-ck*s, its a pretty reliable service. of course you have to do your own due diligence, but they generally point you in the right direction.
  • T
    Tpljmpr5
    Tpljmpr5
    Has Abbot's Libre received approval yet? Wonder how much DXCM will fall when it does? Any guesses??
  • D
    Dani
    Dani
    Where's that idiot Tpljmpr5? The guy who has NEVER been right about this stock.
  • S
    SMD
    SMD
    Great tme to Buy right before earning reports. Dex will beat estimatesdue toan early start on medicare coverage & shipments.
  • T
    Tpljmpr5
    Tpljmpr5
    More laughs from DXCM management: The CEO claims to not have even seen the results of a key trial BUT he knows that they are very confident and its great technology!!!

    "Got it. And then on G6, can you comment at all on the results of the pivotal trial? Were performance results in line with the preclinical data you've previously presented?

    Kevin R. Sayer, DexCom, Inc. - CEO, President and Director

    To the credit of my team, they've not shown me the results of the pivotal study. So I can't comment. And we wouldn't anyway. We'll submit it and it'll be published later. But we're very confident in that system. It's great sensor technology with a very strong algorithm."
  • T
    Tpljmpr5
    Tpljmpr5
    "And it's our job, quite frankly, to get to the cost of the devices down to whereby we can make money there, and we will".

    This sums up everything about this company. They are a mature company in an ever increasingly competitive market with much more elegant solutions on the horizon. Yet even though they were the pioneer in this space and have had it to themselves for well over a decade they STILL cant make money. A company is worth its future free cash flows. Period. Will there be any? Most companies that have a monopoly position like DXCM has enjoyed for years figure out a way to make $$. What does that tell you about this company. If any of you bothered to listen to the call or read the transcript you would also learn that they had to raise more DEBT in the form of a convertible. They cancelled the G5 to focus on G6 (probably cause of lack of funds). They are getting paid ZERO on Medicare and even when this changes the economics are NOT good and adversely affect gross margins. I could go on and on but the rose colored glasses contingent on this board doesn't care. I wish this stock was up 20% today so I could load up again. Sales from pump patients poor, guidance for Q3 weak even though Q3'16 was super soft so guidance should have been strong....and on and on......
  • T
    Tpljmpr5
    Tpljmpr5
    @Dani: I am touched that I am the first person you think of when you wake up. Does that happen every day?? You're sweet.
  • M
    Montique
    Montique
    Dexcom Receiver & Pipeline

    The company was showing off its new touchscreen receiver, expected to launch in the August-September timeframe.

    Also on Friday just before ADA news hit that FDA approved the G5 Mobile app for Android, which had many enthused.

    In a meeting with Dexcom execs, we learned that this leading CGM company has gone from 400 employees 6 years ago to over 2,000 employees currently. Their Gen 6 sensor trials are underway, and the specifics of this system are exciting:

    it will use new sensor membranes and a new algorithm for improved performanceit will block acetaminophen, so patients can finally take Tylenol without messing up their readings (!)it will include a new transmitter and smaller, easier inserter deviceit's designed for 10-day wear, with very little calibration required: only 2 within the first 12 hours, and then one per day from then onthe new sensor will be 30-40% smallerthey hope to file with FDA by Q3 of this year, and launch in 2018

    Regarding future technology, they are of course working with Animas, Tandem and OmniPod on closed-loop system configurations. CEO Kevin Sayer tells us their first product co-developed with Google will be aimed at doctors treating patients with type 2 diabetes. A tiny new sensor code-named Fusion will be "smaller than Abbott Libre, at worst 20% the size of that," Sayer says. Wow! 

    If you're wondering what's going on with Medicare coverage of Dexcom CGM, here's the rub: CMS has mandated that Dexcom ship out to Medicare patients "everything they would need" to use the product. Since calibrations with a fingerstick meter are required, that means Dexcom has to find a traditional meter company to partner with to actually ship meters and test strips in the package with their CGM. Kinda crazy, and definitely creating delays for the company and its customers!

    Last not least, an announcement of Dexcom-Apple Watch integration was made at the recent Apple developers conference -- meaning the CGM data will be beamed directly to your watch. Once this launches, patients can not only ditch the traditional receiver, but could even leave their phones at home and just monitor BGs on their wrist. Cool.

     
  • T
    Tpljmpr5
    Tpljmpr5
    Ouch! This baby is really breaking down. Below $70......soon below $60??? How soon before its back in the $30's? Anyone care to guess.